PE20001600A1 - Derivados de 1,4-diazabiciclo (3.3.2) nonan-4-carboxilatos y carboxamidas, su preparacion y su aplicacion en terapeutica - Google Patents

Derivados de 1,4-diazabiciclo (3.3.2) nonan-4-carboxilatos y carboxamidas, su preparacion y su aplicacion en terapeutica

Info

Publication number
PE20001600A1
PE20001600A1 PE2000000274A PE0002742000A PE20001600A1 PE 20001600 A1 PE20001600 A1 PE 20001600A1 PE 2000000274 A PE2000000274 A PE 2000000274A PE 0002742000 A PE0002742000 A PE 0002742000A PE 20001600 A1 PE20001600 A1 PE 20001600A1
Authority
PE
Peru
Prior art keywords
nonan
carboxamides
derivatives
carboxylates
diazabicyclo
Prior art date
Application number
PE2000000274A
Other languages
English (en)
Inventor
Alistair Lochead
Thierry Gallet
Samir Jeghan
Patrick Lardenois
Alain Nedelec
Original Assignee
Sanofi Synthelabo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Synthelabo filed Critical Sanofi Synthelabo
Publication of PE20001600A1 publication Critical patent/PE20001600A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Anesthesiology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

SE REFIERE A DERIVADOS DE 1,4-DIAZABICICLO [3.2.2] NONAN-4-CARBOXILATOS Y CARBOXAMIDAS DE FORMULA (I), DONDE: X ES O, NZ; Z ES H, ALQUILO C1-C6; n ES 0-2; R1-R5 SON H, HALOGENO, TRIFLUOROMETILO, TRIFLUOROMETOXI, CIANO, OH, ALQUILO C1-C6, FENOXI, FENILO, ENTRE OTROS; O R2 Y R3 JUNTOS SON -OCH2O-, -(CH2)4-. LOS DERIVADOS DE 1,4-DIAZABICICLO [3.2.2] NONAN-4-CARBOXILATO Y CARBOXAMIDAS TIENEN AFINIDAD POR LOS RECEPTORES NICOTINICOS QUE CONTIENEN LA SUBUNIDAD ALFA Y PUEDEN SER UTILES PARA TRATAMIENTO O PREVENCION DE LOS DESORDENES A NIVEL DEL SITEMA NERVIOSO CENTRAL O DEL SISTEMA GASTROINTESTINAL
PE2000000274A 1999-03-30 2000-03-30 Derivados de 1,4-diazabiciclo (3.3.2) nonan-4-carboxilatos y carboxamidas, su preparacion y su aplicacion en terapeutica PE20001600A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9903934A FR2791678B1 (fr) 1999-03-30 1999-03-30 Derives de 1,4-diazabicyclo [3.2.2] nonane-4-carboxylates et -carboxamides, leur preparation et leur application en therapeutique

Publications (1)

Publication Number Publication Date
PE20001600A1 true PE20001600A1 (es) 2001-04-01

Family

ID=9543787

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2000000274A PE20001600A1 (es) 1999-03-30 2000-03-30 Derivados de 1,4-diazabiciclo (3.3.2) nonan-4-carboxilatos y carboxamidas, su preparacion y su aplicacion en terapeutica

Country Status (15)

Country Link
US (1) US6987106B1 (es)
EP (1) EP1165559B1 (es)
JP (1) JP4500454B2 (es)
AR (1) AR023188A1 (es)
AT (1) ATE232865T1 (es)
AU (1) AU3301800A (es)
CO (1) CO5180557A1 (es)
DE (1) DE60001451T2 (es)
DK (1) DK1165559T3 (es)
ES (1) ES2192520T3 (es)
FR (1) FR2791678B1 (es)
PE (1) PE20001600A1 (es)
TW (1) TWI221843B (es)
UY (1) UY26082A1 (es)
WO (1) WO2000058311A1 (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60109924T2 (de) 2000-05-25 2006-02-09 Targacept, Inc. Heteroaryldiazabicycloalkane als liganden für den nikotinischen acetylcholin-rezeptor
US6624167B1 (en) 2000-08-04 2003-09-23 Targacept, Inc. Pharmaceutical compositions and methods for use
ES2275808T3 (es) * 2001-02-06 2007-06-16 Pfizer Products Inc. Composiciones farmaceuticas para el tratamiento de trastornos del snc y otros trastornos.
DE10164139A1 (de) 2001-12-27 2003-07-10 Bayer Ag 2-Heteroarylcarbonsäureamide
SE0202430D0 (sv) * 2002-08-14 2002-08-14 Astrazeneca Ab New Compounds
SE0202465D0 (sv) * 2002-08-14 2002-08-14 Astrazeneca Ab New compounds
WO2004029050A1 (en) 2002-09-25 2004-04-08 Memory Pharmaceuticals Corporation Indazoles, benzothiazoles, and benzoisothiazoles, and preparation and uses thereof
JP2006519208A (ja) * 2003-02-27 2006-08-24 ニューロサーチ、アクティーゼルスカブ 新規ジアザビシクロアリール誘導体
EP1699802A1 (en) * 2003-12-22 2006-09-13 AstraZeneca AB Nicotinic acetylcholine receptor ligands
TW200529860A (en) * 2003-12-22 2005-09-16 Astrazeneca Ab Nicotinic acetylcholine receptor ligands
JP4824578B2 (ja) 2003-12-22 2011-11-30 メモリー・ファーマシューティカルズ・コーポレイション インドール類、１，２−ベンズイソオキサゾール類、および１，２−ベンゾイソチアゾール類、ならびにそれらの製造と使用
BRPI0506881A (pt) * 2004-02-04 2007-06-26 Neurosearch As derivado de arila diazabicìclica, composição farmacêutica, uso de um derivado de arila diazabicìclica, e, método de tratamento, prevenção ou alìvio de uma doença ou distúrbio ou condição de um corpo de animal vivo
CA2560741C (en) 2004-03-25 2013-08-06 Memory Pharmaceuticals Corporation Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, and preparation and uses thereof
US7488737B2 (en) 2004-04-22 2009-02-10 Memory Pharmaceutical Corporation Indoles, 1H-indazoles, 1,2-benzisoxazoles, 1,2-benzoisothiazoles, and preparation and uses thereof
JP2007538011A (ja) 2004-05-07 2007-12-27 メモリー・ファーマシューティカルズ・コーポレイション １ｈ−インダゾール、ベンゾチアゾール、１，２−ベンゾイソキサゾール、１，２−ベンゾイソチアゾール、およびクロモン、ならびにそれらの調製および使用
EP1802616B1 (en) * 2004-10-15 2011-01-12 NeuroSearch A/S Novel azabicyclic aryl derivatives and their medical use
US7625924B2 (en) 2004-12-22 2009-12-01 Memory Pharmaceuticals Corporation Nicotinic alpha-7 receptor ligands and preparation and uses thereof
US8106066B2 (en) 2005-09-23 2012-01-31 Memory Pharmaceuticals Corporation Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, pyrazolopyridines, isothiazolopyridines, and preparation and uses thereof
JP2009526776A (ja) * 2006-02-14 2009-07-23 ノイロサーチ アクティーゼルスカブ 新規なジアザビシクロアルカン誘導体及びその医療上の使用
JP2007217370A (ja) * 2006-02-17 2007-08-30 Nard Inst Ltd ポジトロン断層撮影法および該方法に用いるポジトロン放出化合物
EP2029594B1 (en) 2006-05-23 2010-10-20 NeuroSearch A/S Novel 1,4-diaza-bicyclo[3.2.2]nonane derivatives and their medical use
US20100234349A1 (en) 2006-09-04 2010-09-16 Olsen Gunnar M Pharmaceutical combinations of a nicotine receptor modulator and a cognitive enhancer
WO2008119710A1 (en) * 2007-03-30 2008-10-09 Neurosearch A/S Two-phase test method for characterizing the effect of a chemical compound on a test animal and maze for carrying out the method
SA08290475B1 (ar) * 2007-08-02 2013-06-22 Targacept Inc (2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه
FR2931677B1 (fr) * 2008-06-02 2010-08-20 Sanofi Aventis Association d'un agoniste partiel des recepteurs nicotiniques et d'un inhibiteur d'acetylcholinesterase, composition la contenant et son utilisation dans le traitement des troubles cognitifs
FR2931823B1 (fr) 2008-06-02 2012-08-17 Sanofi Aventis Sel de fumarate du 1,4-diazabicyclo°3.2.2!nonane-carboxylate de 4-bromophenyle, ses formes cristallines, leur preparation et leur utilisation en therapeutique
EP2540297B1 (en) 2008-11-19 2015-04-08 Forum Pharmaceuticals Inc. Treatment of Cognitive Disorders with (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof
TW201031664A (en) 2009-01-26 2010-09-01 Targacept Inc Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide
RU2011150248A (ru) * 2009-05-11 2013-06-20 Энвиво Фармасьютикалз, Инк. Лечение когнитивных расстройств с определенными рецепторами альфа-7 никотиновой кислоты в комбинации с ингибиторами ацетилхолинэстеразы
CN105837566B (zh) 2010-05-17 2018-02-06 富瑞姆制药公司 (R)‑7‑氯‑N‑(奎宁环‑3‑基)苯并[b]噻吩‑2‑甲酰胺盐酸盐单水合物的晶型
EP3673906A1 (en) * 2011-03-18 2020-07-01 Genzyme Corporation Glucosylceramide synthase inhibitors
EP2846796A4 (en) 2012-05-08 2015-10-21 Forum Pharmaceuticals Inc METHODS OF MAINTAINING, PROCESSING OR ENHANCING COGNITIVE FUNCTION
MA37975B2 (fr) 2012-09-11 2021-03-31 Genzyme Corp Inhibiteurs de synthase de glucosylcéramide
IL300090A (en) 2020-07-24 2023-03-01 Genzyme Corp Pharmaceutical preparations containing VENGLUSTAT

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0235878A3 (en) * 1986-01-16 1989-06-14 Beecham Group Plc Novel compounds
JP2668670B2 (ja) * 1995-03-24 1997-10-27 日本たばこ産業株式会社 ジアザビシクロ［３．３．１］ノナン誘導体、その中間体及びその医薬用途
AU7149798A (en) * 1997-06-30 1999-01-19 R.J. Reynolds Tobacco Company 3-pyridyl-1-aza-bicyclo-alkane derivatives for prevention and treatment of cn s disorders

Also Published As

Publication number Publication date
ES2192520T3 (es) 2003-10-16
FR2791678A1 (fr) 2000-10-06
FR2791678B1 (fr) 2001-05-04
DE60001451T2 (de) 2004-01-15
JP2002540208A (ja) 2002-11-26
EP1165559B1 (fr) 2003-02-19
CO5180557A1 (es) 2002-07-30
DK1165559T3 (da) 2003-06-10
EP1165559A1 (fr) 2002-01-02
DE60001451D1 (de) 2003-03-27
WO2000058311A1 (fr) 2000-10-05
US6987106B1 (en) 2006-01-17
TWI221843B (en) 2004-10-11
JP4500454B2 (ja) 2010-07-14
AU3301800A (en) 2000-10-16
ATE232865T1 (de) 2003-03-15
UY26082A1 (es) 2000-10-31
AR023188A1 (es) 2002-09-04

Similar Documents

Publication Publication Date Title
PE20001600A1 (es) Derivados de 1,4-diazabiciclo (3.3.2) nonan-4-carboxilatos y carboxamidas, su preparacion y su aplicacion en terapeutica
TNSN96075A1 (fr) N-(indole-2-carbonyl) - beta- alaninamides substitues et leurs derives, servant d'agents antidiabetiques
DK1140088T3 (da) Orale methylphenidatformuleringer med reguleret/modificeret frigivelse
NO20034230L (no) 1,2,3,4-tetrahydroisokinolin-derivater som urotensin II reseptor-antagonister
PE20020719A1 (es) Derivados de carbamato de quinuclidina como agentes antimuscarinicos m3
NZ515705A (en) Substituted phenylpropionic acid derivatives as agonists to human peroxisome proliferator-activated receptor (PPAR) alpha
MY144897A (en) 2,3,4,9-tetrahydro-1h-carbazole derivatives as crth2 receptor antagonists
NO972324L (no) Orale blandinger inneholdende Ondansetron
PE20011114A1 (es) Decahidro-isoquinolinas
ATE275397T1 (de) Zusammensetzungen, enthaltend blocker des renalen zelltransfers von l-dopa zur behandlung der parkinson-krankheit
ATE416767T1 (de) 5-halo-tryptaminderivate als 5-ht6 und/oder 5-ht7 rezeptorliganden
AR029190A1 (es) Composiciones que contienen derivados del acido hidroxieicosatetraenoico y uso para la manufactura de un medicamento en el tratamiento de trastornos del ojo seco
PE20061318A1 (es) Nuevas combinaciones terapeuticas para el tratamiento o la prevencion de trastornos psicoticos
ATE293448T1 (de) Benzo(d)azepin-derivative als 5-ht6-rezeptor- antagonisten
PE20001543A1 (es) Derivados de piridopiranoacepinas, su preparacion y su aplicacion en terapeutica
FI980471A (fi) 1,3-substituoidut sykloalkeenit ja sykloalkaanit keskushermostoon vaikuttavina aineina
BR0008509A (pt) Composição farmacêutica oral estabilizada contendo iodeto e iodato e método
PE20001583A1 (es) Derivados de la 1-arenosulfonil-2-arilo-pirrolidina y de la piperidina
GB8518658D0 (en) Medicaments
BG94282A (bg) 2,9-дизаместени-4н-пиридо/1,2,-а/пиримидин-4-они
ES2160649T3 (es) Nuevos compuestos lactamicos y procedimientos para su preparacion.
AR007352A1 (es) Derivados sustituidos de bencimidazol, proceso para su preparacion, formulacion farmaceutica que los contiene, y uso de dichos derivados para la manufactura de medicamentos
SE0102055D0 (sv) New Compounds
ATE218860T1 (de) Verwendung von 3,4-diphenylchromanen zur herstellung eines arzneimittels zur behandlung bzw. vorbeugung des prostatakarzinoms
DE69808440D1 (de) Verwendung von (+)mefloquine zur behandlung von malaria

Legal Events

Date Code Title Description
FA Abandonment or withdrawal